In April 2020, the FDA requested the removal of Zantac and other ranitidine medications from the market. This removal was sparked by new research indicating the presence of NDMA, a harmful probable ...

The first lawsuit claiming that gastrointestinal drug Zantac causes cancer has been voluntarily dismissed a week before it was due to come to trial, in an early victory for the pharma companies ...

A hearing will get underway in Delaware later today in the latest phase of GSK’s attempts to defend itself from allegations that its Zantac drug caused cancer in patients. The three-day hearing ...

NEW YORK, NY / ACCESS Newswire / March 19, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a ...

Feb 25 (Reuters) - Boehringer Ingelheim has prevailed in the trial of two lawsuits claiming that its discontinued heartburn drug Zantac caused cancer, both of which had previously ended with hung ...

NEW YORK CITY, NY / ACCESS Newswire / March 19, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

An Illinois state jury has today ruled in favor of Boehringer Ingelheim, rejecting claims from two men who alleged that their prostate cancer diagnoses were caused by long-term use of the company’s ...

Robbins LLP reminds stockholders that a class action was filed on behalf of all purchasers of the American Depository Receipts ("ADRs") of GSK PLC (NYSE: GSK) between February 5, 2020 and August 14, ...

The Law Offices of Frank R. Cruz announces that investors with losses related to GSK plc. ("GSK" or the "Company") have opportunity to lead the securities fraud class action ...

Generic drugmakers and hospital pharmacists warn that added financial pressure from tariffs could strain the nation's generic drug supplies.

An Illi­nois ju­ry ruled in fa­vor of Boehringer In­gel­heim in Zan­tac lit­i­ga­tion brought by two prostate can­cer pa­tients, the com­pa­ny con­firmed.